Science publication that confirms mechanism of action of simufilam, a novel drug candidate for Alzheimer’s Disease
Cassava Sciences, Inc. announced the publication of new research that confirms the biological activity of simufilam
Simufilam is Cassava Sciences’ novel drug candidate for people with Alzheimer’s disease dementia and is currently under evaluation in a pair of global Phase III clinical trials. Researchers at the Cochin Institute (Paris, France) used a highly precise cell-based assay to show that simufilam interrupts amyloid binding to the alpha 7 nicotinic acetylcholine receptor. Cassava Sciences believes this protein interaction underlies simufilam’s mechanism of action in Alzheimer’s disease. The research appears in a special issue of International Journal of Molecular Sciences, a peer-reviewed scientific publication.
“Four academic institutions have now generated data in support of the biological activity of simufilam,” said Remi Barbier, President & CEO. “They can’t all be wrong.”
“Today’s data are an elegant confirmation of simufilam’s mechanism of action,” said Lindsay Burns, PhD, VP of Neuroscience at Cassava Sciences and co-author on the publication. “They show that simufilam potently disrupts a known pathological action of amyloid beta using a robust and highly sensitive assay based on a technique called TR-FRET.”
See- "Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer’s Disease"-by Hoau-Yan Wang,Erika Cecon ORCID, Julie Dam ,Zhe Pei1, Ralf Jockers ORCID and Lindsay H. Burns .Int. J. Mol. Sci. 2023, 24(18), 13927; https://doi.org/10.3390/ijms241813927 (registering DOI).Published: 11 September 2023.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.